|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0021735,
umls-concept:C0021747,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0278996,
umls-concept:C0280055,
umls-concept:C0282461,
umls-concept:C0460004,
umls-concept:C0596382,
umls-concept:C1257890,
umls-concept:C1522484,
umls-concept:C1709059
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-3-24
|
|
pubmed:abstractText |
In preclinical experiments, interferon alfa modulates the anticancer activity of fluorouracil (5-FU) and cisplatin (CDDP). To test this effect clinically in patients with recurrent or metastatic head and neck cancer (RMHNC), a multicenter randomized controlled trial with CDDP and 5-FU with or without interferon alfa-2b (IFNalpha) was performed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:ArvayCC,
pubmed-author:CvitkovicEE,
pubmed-author:GoreMM,
pubmed-author:JacobHH,
pubmed-author:JiminezUU,
pubmed-author:JohnsonJJ,
pubmed-author:KosmidisPP,
pubmed-author:LangeckerPP,
pubmed-author:LewensohnRR,
pubmed-author:OliveiraJJ,
pubmed-author:RiviereAA,
pubmed-author:RobbinsKK,
pubmed-author:SchüllerJJ,
pubmed-author:SchrijversDD,
pubmed-author:SzpirglasHH,
pubmed-author:VokesEE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1054-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9508190-Adult,
pubmed-meshheading:9508190-Aged,
pubmed-meshheading:9508190-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9508190-Cisplatin,
pubmed-meshheading:9508190-Female,
pubmed-meshheading:9508190-Fluorouracil,
pubmed-meshheading:9508190-Head and Neck Neoplasms,
pubmed-meshheading:9508190-Humans,
pubmed-meshheading:9508190-Interferon-alpha,
pubmed-meshheading:9508190-Male,
pubmed-meshheading:9508190-Middle Aged,
pubmed-meshheading:9508190-Neoplasm Recurrence, Local,
pubmed-meshheading:9508190-Recombinant Proteins,
pubmed-meshheading:9508190-Remission Induction,
pubmed-meshheading:9508190-Survival Analysis
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
|
|
pubmed:affiliation |
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium. dirk.schrijvers@uza.via.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
